75 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp04180 | LL-III | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4 ± 1 µM |
| dbacp04181 | LL-III | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 18 ±4 µM |
| dbacp04182 | LL-III | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 3 µM |
| dbacp04183 | LL-III/1 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3 ± 1 µM |
| dbacp04184 | LL-III/1 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 12 ± 3 µM |
| dbacp04185 | LL-III/1 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 3 ± 1 µM |
| dbacp04186 | LL-III/10 | KNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9 ± 4 µM |
| dbacp04187 | LL-III/10 | KNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04188 | LL-III/10 | KNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 µM |
| dbacp04189 | LL-III/11 | VNWKKIILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 ± 1 µM |
| dbacp04190 | LL-III/11 | VNWKKIILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 48 µM |
| dbacp04191 | LL-III/11 | VNWKKIILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 ± 1 µM |
| dbacp04192 | LL-III/12 | vnwkkilgkiikvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 6 ± 2 µM |
| dbacp04193 | LL-III/12 | vnwkkilgkiikvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04194 | LL-III/12 | vnwkkilgkiikvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 2 µM |
| dbacp04195 | LL-III/15 | VNFKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7 ± 1 µM |
| dbacp04196 | LL-III/15 | VNFKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 42 µM |
| dbacp04197 | LL-III/15 | VNFKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 ± 3 µM |
| dbacp04198 | LL-III/16 | VN-NAl-KKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 6 ± 1 µM |
| dbacp04199 | LL-III/16 | VN-NAl-KKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04200 | LL-III/16 | VN-NAl-KKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04201 | LL-III/17 | VNWRRILGRIIRVVR | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9 µM |
| dbacp04202 | LL-III/17 | VNWRRILGRIIRVVR | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04203 | LL-III/17 | VNWRRILGRIIRVVR | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04204 | LL-III/18 | KNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3 µM |
| dbacp04205 | LL-III/18 | KNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04206 | LL-III/18 | KNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 7 ± 2 µM |
| dbacp04207 | LL-III/19 | VNWKK-Aib-LGK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3 ± 1 µM |
| dbacp04208 | LL-III/19 | VNWKK-Aib-LGK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 28 µM |
| dbacp04209 | LL-III/19 | VNWKK-Aib-LGK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 8 ± 2 µM |
| dbacp04210 | LL-III/2 | NVWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | Not found |
| dbacp04211 | LL-III/2 | NVWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 11 µM |
| dbacp04212 | LL-III/2 | NVWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 7 ± 2 µM |
| dbacp04213 | LL-III/22 | KNWKK-Aib-LKK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 11 ± 7 µM |
| dbacp04214 | LL-III/22 | KNWKK-Aib-LKK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04215 | LL-III/22 | KNWKK-Aib-LKK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 25 ± 4 µM |
| dbacp04216 | LL-III/23 | VNWKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4 µM |
| dbacp04217 | LL-III/23 | VNWKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 15 µM |
| dbacp04218 | LL-III/23 | VNWKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 µM |
| dbacp04219 | LL-III/24 | VNWOOILGOIIOVVO | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3 ± 1 µM |
| dbacp04220 | LL-III/24 | VNWOOILGOIIOVVO | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04221 | LL-III/24 | VNWOOILGOIIOVVO | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 2 µM |
| dbacp04222 | LL-III/25 | vnwkkllgkllkvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4 ± 2 µM |
| dbacp04223 | LL-III/25 | vnwkkllgkllkvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 20 µM |
| dbacp04224 | LL-III/25 | vnwkkllgkllkvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 µM |
| dbacp04225 | LL-III/26 | VYWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 5 ±1 µM |
| dbacp04226 | LL-III/26 | VYWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 30 µM |
| dbacp04227 | LL-III/26 | VYWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 µM |
| dbacp04228 | LL-III/27 | VNWKKVLGKVVKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 13 ± 2 µM |
| dbacp04229 | LL-III/27 | VNWKKVLGKVVKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 100 µM |
| dbacp04230 | LL-III/27 | VNWKKVLGKVVKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 18 µM |
| dbacp04231 | LL-III/3 | VNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | Not found |
| dbacp04232 | LL-III/3 | VNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp04233 | LL-III/3 | VNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04234 | LL-III/34 | NKWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 5 ± 2 µM |
| dbacp04235 | LL-III/34 | NKWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 37 µM |
| dbacp04236 | LL-III/34 | NKWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 3 µM |
| dbacp04237 | LL-III/36 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 8 µM |
| dbacp04238 | LL-III/36 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04239 | LL-III/36 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04240 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 5 ± 1 µM |
| dbacp04241 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 13 µM |
| dbacp04242 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 ± 1 µM |
| dbacp04243 | LL-III/4 | VNWKKILGKIKKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7 ± 1 µM |
| dbacp04244 | LL-III/4 | VNWKKILGKIKKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : > 40 µM |
| dbacp04245 | LL-III/4 | VNWKKILGKIKKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 18 µM |
| dbacp04246 | LL-III/6 | VNWKKILPKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : > 40 µM |
| dbacp04247 | LL-III/6 | VNWKKILPKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04248 | LL-III/6 | VNWKKILPKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 ± 3 µM |
| dbacp04249 | LL-III/8 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 12 ± 1 µM |
| dbacp04250 | LL-III/8 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | Not found |
| dbacp04251 | LL-III/8 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 µM |
| dbacp04252 | LL-III/9 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3 ± 1 µM |
| dbacp04253 | LL-III/9 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | SW | Colon cancer | IC50 : 25 ± 5 µM |
| dbacp04254 | LL-III/9 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |